Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment

Haploidentical stem cell transplantation (haplo SCT) in Stage IV neuroblastoma relapsed patients has been proven efficacious, while immunotherapy utilizing the anti-GD2 antibody dinutuximab beta has become a standard treatment for neuroblastoma. The combinatorial therapy of haplo SCT and dinutuximab...

Full description

Bibliographic Details
Main Authors: Christian Martin Seitz, Tim Flaadt, Markus Mezger, Anne-Marie Lang, Sebastian Michaelis, Marie Katz, Desireé Syring, Alexander Joechner, Armin Rabsteyn, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Holger N. Lode, Sile F. Yang, Daniel Atar, Anna-Sophia Mast, Sophia Scheuermann, Florian Heubach, Rupert Handgretinger, Peter Lang, Patrick Schlegel
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
neuroblastoma
immunomonitoring immunotherapy
GD2 antibody therapy
haploidentical allogeneic stem cell transplantation
antibody-dependent cellular cytotoxicity
complement-dependent cytotoxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.690467/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.690467/full

Similar Items